{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"16.3","value":"7.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The PFS is defined as the duration of time from the start of treatment to time of progression or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"A: Tiered Dose Escalation/Phase II Dose. Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m\\^2. Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m\\^2. Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m\\^2.\n\nB: Maintenance Therapy - Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first.","id":"OG000","title":"Dose Escalation Followed by Maintenance Therapy"}],"paramType":"MEDIAN","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"2 Years, 9 Months","title":"Number of Months of Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}